Bias within economic evaluations – the impact of considering the future entry of lower-cost generics on currently estimated incremental cost-effectiveness ratios of a new drug

BACKGROUND: Most economic evaluation models compare a new patented drug (NPRx) to a generic comparator. Drug costs within these models are usually limited to the retail cost of both drugs at the time of model conception. However, the retail cost of the NPRx is expected to drop once generic versions...

Descripción completa

Detalles Bibliográficos
Autores principales: Guertin, Jason R, Mitchell, Dominic, Ali, Farzad, LeLorier, Jacques
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2015
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4605233/
https://www.ncbi.nlm.nih.gov/pubmed/26504402
http://dx.doi.org/10.2147/CEOR.S90386

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4605233/
https://www.ncbi.nlm.nih.gov/pubmed/26504402
http://dx.doi.org/10.2147/CEOR.S90386

Ejemplares similares